Product nameAnti-ITPA antibody
See all ITPA primary antibodies
DescriptionRabbit polyclonal to ITPA
Tested applicationsSuitable for: ICC/IF, WBmore details
Species reactivityReacts with: Human
Synthetic peptide corresponding to Human ITPA aa 150 to the C-terminus conjugated to keyhole limpet haemocyanin.
(Peptide available as
- Recombinant Human ITPA protein (ab123470) can be used as a positive control in WB. This antibody gave a positive signal in HepG2 Whole Cell Lysate.
This product was previously labelled as Inosine triphosphate pyrophosphatase
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.02% Sodium Azide
Constituents: 1% BSA, PBS, pH 7.4
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab79967 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: Use at an assay dependent dilution. Detects a band of approximately 24 kDa (predicted molecular weight: 21 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionHydrolyzes ITP and dITP to their respective monophosphate derivatives. Xanthosine 5'-triphosphate (XTP) is also a potential substrate. May be the major enzyme responsible for regulating ITP concentration in cells.
Tissue specificityUbiquitous. Highly expressed in heart, liver, sex glands, thyroid and adrenal gland.
Involvement in diseaseDefects in ITPA are the cause of inosine triphosphate pyrophosphohydrolase deficiency (ITPA deficiency) [MIM:147520]. It is a common inherited trait characterized by the abnormal accumulation of inosine triphosphate (ITP) in erythrocytes and also leukocytes and fibroblasts. The pathological consequences of ITPA deficiency, if any, are unknown. However, it might have pharmacogenomic implications and be related to increased drug toxicity of purine analog drugs. Three different human populations have been reported with respect to their ITPase activity: high, mean (25% of high) and low activity. The variant Thr-32 is associated with complete loss of enzyme activity, may be by altering the local secondary structure of the protein. Heterozygotes for this polymorphism have 22.5% of the control activity: this is consistent with a dimeric structure of the enzyme.
Sequence similaritiesBelongs to the HAM1 NTPase family.
- Information by UniProt
- C20orf37 antibody
- dJ794I6.3 antibody
- HLC14-06-P antibody
Anti-ITPA antibody (ab79967) at 1 µg/ml + HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate at 10 µg
Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 21 kDa
Observed band size: 24 kDa why is the actual band size different from the predicted?
Additional bands at: 125 kDa, 70 kDa, 75 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 10 minutes
The additional band observed at 70 kDa is comparable to the molecular weight seen with other commercially available antibodies to ITPA.
ICC/IF image of ab79967 stained HeLa cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab79967, 5µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM. This antibody also gave a positive result in 100% methanol fixed (5 min) Hek293, HepG2 and MCF7 cells at 5µg/ml.
ab79967 has not yet been referenced specifically in any publications.